Novo Nordisk A/S
Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground
Eli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medications: pills. Both companies expect to launch oral obesity drugs in the U.S. next year, once regulators approve them. Daily pills could introduce more people to GLP-1s, the class of medicine that’s best known for weekly shots. But […]
Read More
Health care inflation rises as patients, employers brace for biggest jump in health spending in 15 years
Jose Luis Pelaez Inc | Digitalvision | Getty Images Health-care inflation is fueling higher coverage costs, setting the stage for what could be the largest increase in health-care spending by large employers in 15 years. Medical care costs in August rose 4.2% on an annualized basis, according to the Labor Department’s Consumer Price Index, compared […]
Read More
Healthy Returns: New FDA rules affect copycat GLP-1s, and Apple adds health tools to its latest Watch
FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009. Jason Reed | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The Food […]
Read More
Healthy Returns: Novo Nordisk’s head of research and development previews the first-ever obesity pill
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. We’re inching closer to having the first-ever needle-free weight loss drug. That’s thanks to Novo Nordisk, which expects a U.S. approval for its daily pill for chronic […]
Read More
Healthy Returns: Eli Lilly’s chief scientific officer breaks down the latest obesity pill data
The Eli Lilly headquarters in Indianapolis, Indiana, on Aug. 15, 2024. AJ Mast | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Eli Lilly‘s closely watched obesity pill is inching closer […]
Read More
Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval
Eli Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023. Mike Blake | Reuters Eli Lilly on Tuesday said its daily weight loss pill helped patients with obesity and Type 2 diabetes shed weight in a late-stage trial, meeting the study’s main goal and clearing the way for the company to […]
Read More
A world on weight loss drugs: How GLP-1s are reshaping the economy
Eternalcreative | Istock | Getty Images Miracle drugs, obesity treatments and skinny jabs. Call them what you will, few drugs have had a more transformative effect on Wall Street and waistlines over recent decades than GLP-1s. Familiarly known under the brand names Wegovy and Zepbound, Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medication used to […]
Read More
Eli Lilly’s obesity pill remains a viable rival to Novo’s oral Wegovy despite data that underwhelmed investors
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly‘s stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street. In a key late-stage trial, […]
Read More
European pharma is spared worst-case U.S. tariffs. Investors still don’t trust the deal
European pharmaceutical firms gained some much-desired clarity on Thursday, with news that U.S. tariffs will be capped at up to 15% — but a muted market reaction appeared to reflect skepticism among investors on whether the rate is set in stone. Fresh details on the European Union’s trade agreement with the White House revealed that […]
Read More
FDA approves first-ever glucose monitoring system for weight loss from Signos
Woman with Signos wearable and app Source: Signos The Food and Drug Administration on Wednesday approved the first-ever glucose monitoring system specifically for weight loss from the startup Signos, establishing a new option for Americans to manage their weight. Current treatment options for losing weight – popular drugs like GLP-1s and surgical interventions – are […]
Read More